Search Results
Your search for ,sIX matches 2928 pages
Showing 2851 - 2900Superior Progression-Free Survival With Obinutuzumab/Chlorambucil vs Rituximab/Chlorambucil in Previously Untreated CLL With Coexisting Conditions
Obinutuzumab (Gazyva) is a glycoengineered type 2 anti-CD20 antibody that appears to exhibit increased activity against chronic lymphocytic leukemia cells (CLL), with increased antibody-dependent cellular cytotoxicity and reduced complement-dependent cytotoxicity, compared with rituximab (Rituxan). ...
Anti–PD-1 Antibody Pidilizumab Plus Rituximab Shows High Activity in Relapsed Follicular Lymphoma
Antitumor immune responses may be inhibited by immune checkpoints in the tumor microenvironment including effects of PD-1 (programmed cell death 1), a co-inhibitory receptor on tumor T cells that impairs T-cell function. In a phase II study reported in The Lancet Oncology, Westin et al assessed the ...
Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years
In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
Less Is More: Postoperative Radiation May Be Avoided in Older Women With Estrogen Receptor–Rich Tumors
Among older women with hormone receptor–positive breast cancer, it is reasonable to omit whole-breast radiation therapy after breast-conserving surgery and neoadjuvant hormone therapy if the patient’s tumors have high levels of estrogen receptor expression, but radiation should remain...
ASH 2013: Brentuximab Vedotin Shows Promising Activity in Non-Hodgkin Lymphoma
The antibody-drug conjugate brentuximab vedotin (Adcetris) has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, in a study presented at the American Society of Hematology (ASH) Annual Meeting and Exposition...
Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies
Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...
Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....
Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Digital Breast Tomosynthesis Increases Cancer Detection and Reduces Recall Rates
Compared to traditional mammography, three-dimensional (3D) mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer call-backs in a large screening study at the Hospital of the University of Pennsylvania, researchers reported today at the 99th...
Disease-Free Survival Is Acceptable Surrogate for Overall Survival in Trials of Adjuvant Chemotherapy for Gastric Cancers
Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting, the GASTRIC group concluded after conducting a meta-analysis of data from 3,288 individual patients enrolled in 14 randomized clinical trials. The trials...
Epigenetic Modification of HAND2 May Be Associated With the Development of Endometrial Cancer
In a study reported in the journal PLoS One, Allison Jones, MD, of the Elizabeth Garrett Anderson Institute for Women’s Health, University College London, and colleagues analyzed the functional role of epigenetic factors in endometrial cancer development. They found that HAND2 methylation...
Brentuximab Vedotin Plus ABVD or AVD Is Highly Active in Newly Diagnosed Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) is active in patients with relapsed/refractory Hodgkin’s lymphoma. In a phase I study reported in The Lancet Oncology, Anas Younes, MD, of Memorial Sloan-Kettering Cancer Center (formerly of The University of Texas MD Anderson Cancer Center), and colleagues...
MicroRNA Signature Predicts Risk of Recurrence After Surgery for Stage II Colon Cancer
In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...
International Ki67 Reproducibility Study Shows High Intralaboratory but Only Moderate Interlaboratory Reproducibility
In a study reported in Journal of the National Cancer Institute, Mei-Yin C. Polley, PhD, of the National Cancer Institute, and colleagues assessed intralaboratory and interlaboratory variability in Ki67 scoring. They found high intralaboratory reproducibility but only moderate interlaboratory...
Pegfilgrastim Prophylaxis Throughout Chemotherapy Is More Effective in Preventing Febrile Neutropenia in Breast Cancer (and More Costly)
Available data suggest that risk of febrile neutropenia is greatest during the first two cycles of chemotherapy in patients with breast cancer. In a study reported in the Journal of Clinical Oncology, Maureen J. Aarts of Maastricht University Medical Centre in the Netherlands, and colleagues...
Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia
Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...
Early Autologous Transplantation Improves Progression-Free Survival in Aggressive Non-Hodgkin Lymphoma
The strategy of autologous stem cell transplantation as consolidation in high-intermediate– or high-risk diffuse aggressive non-Hodgkin lymphoma (NHL) has not been specifically examined in the rituximab (Rituxan) era. In a phase III trial (Southwest Oncology Group 9704) reported in The New...
Dose-Limiting Late Toxicity Observed After Hypofractionated Dose-Escalated Radiotherapy in NSCLC
In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...
Perioperative FOLFOX4 Does Not Improve Overall Survival vs Surgery Alone in Patients With Resectable Liver Metastases From Colorectal Cancer
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
New Biomarker May Help Guide Treatment of Melanoma Patients
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held...
Association Between Prevalence of Symptoms and Impaired Health-Related Quality of Life in Adult Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, I-Chan Huang, PhD, of University of Florida at Gainesville, and colleagues investigated the association between prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer enrolled in the St. Jude...
Improved Progression-Free but Not Overall Survival With Addition of Maintenance Erlotinib to Bevacizumab After Chemotherapy Plus Bevacizumab in NSCLC
In the phase IIIB ATLAS trial reported in the Journal of Clinical Oncology, Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, and colleagues assessed the addition of maintenance erlotinib (Tarceva) to bevacizumab (Avastin) following chemotherapy plus bevacizumab in first-line treatment of ...
Most Common Tumors Are Driven by Two to Six DNA Mutations
A genetic analysis of 3,281 tumors from 12 cancer types, including breast, lung, endometrial, glioblastoma multiforme, ovarian, colon, and acute myeloid leukemia, has found 127 significantly mutated genes that appear to be involved in either cancer initiation or progression. Although the average...
Simple Blood Test May Diagnose Lung and Other Cancers
A simple blood test that measures serum free fatty acids and their metabolites may detect early-stage lung cancer and its recurrence, according to a study from The Cleveland Clinic presented at the ANESTHESIOLOGY™ 2013 Annual Meeting in San Francisco (Abstract A4267). The study was presented ...
ASCO and the College of American Pathologists Issue Updated Guideline on HER2 Testing in Breast Cancer
ASCO and the College of American Pathologists (CAP) today issued a joint, updated guideline to improve the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The six-recommendation guideline is based on a systematic review of...
Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...
Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma
Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
Japanese Study Shows Endoscopic Dual Tracer Method for Sentinel Node Mapping in Gastric Cancer Is Safe and Accurate
In a study reported in Journal of Clinical Oncology, Yuko Kitagawa, MD, FACS, of Keio University School of Medicine, and colleagues found that sentinel node mapping using a standardized dual tracer endoscopic injection technique was safe and accurate in patients with gastric cancer. Study Details ...
Exploratory Analysis Suggests Response-Guided Neoadjuvant Therapy for Breast Cancer May Improve Survival
In an exploratory analysis of long-term survival data from the GeparTrio trial reported in Journal of Clinical Oncology, Gunter von Minckwitz, MD, of the German Breast Group in Neu-Isenburg, and colleagues found that response-guided neoadjuvant chemotherapy appears to improve disease-free survival...
Phase II Study Shows Durable Effect of Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma
In a phase II study (MCL-001, EMERGE) reported in Journal of Clinical Oncology, Andre Goy, MD, of Hackensack University Medical Center, and colleagues evaluated the use of single-agent lenalidomide (Revlimid) in bortezomib (Velcade)-treated patients who had relapsed/refractory mantle cell lymphoma. ...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
Quality of Life Improves Over Time and Is Similar in Long-Term Breast Cancer Survivors and Women With No History of Breast Cancer
In a study reported in Journal of Clinical Oncology, Pamela J. Goodwin, MD, and Tina Hsu of University of Toronto and colleagues assessed changes in quality of life from time of breast cancer diagnosis to long-term survivorship and compared quality of life in long-term survivors to that of...
No Overall Survival Benefit With Brivanib in Advanced Hepatocellular Carcinoma Patients After Sorafenib Failure or Intolerance
The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...
Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer
The primary analysis of the Japanese JGOG 3016 trial showed that dose-dense paclitaxel plus carboplatin significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer. In a long-term...
Meta-Analysis Indicates BEACOPPescalated Is Superior in Advanced Hodgkin Lymphoma
Studies evaluating two standards of care in adults with advanced Hodgkin lymphoma—ie, increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine (Matulane), and prednisone (BEACOPPescalated) and doxorubicin, bleomycin, vinblastine, and dacarbazine...
NSABP B-38 Trial Shows No Benefit of Adding Fourth Drug to Standard Adjuvant Treatment in Women With Node-Positive Breast Cancer
Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. As reported in Journal of Clinical Oncology by Sandra M. Swain, MD, FACP, of Washington Cancer Institute–MedStar Washington Hospital Center, and colleagues,...
Multicenter Trial Finds BI-RADS 3 Breast Lesions Have Low Cancer Rate
Based on data from a multisite imaging trial involving more than 2,600 women, researchers say breast lesions categorized as “probably benign” on supplemental screening ultrasound could be reevaluated with imaging in 12 months, reducing patient anxiety, follow-up exams, and unnecessary...
Risk-Directed Treatment Intensification Significantly Improves Outcomes in Children With ALL and Intrachromosomal Amplification of Chromosome 21
In a study reported in Journal of Clinical Oncology, Anthony V. Moorman, PhD, of Newcastle University, and colleagues compared outcomes in children and adolescents with B-cell precursor acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21) in a trial in...
No Benefit/Detriment of New Donor in Second Hematopoietic Stem Cell Transplantation for Leukemia Relapse
Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after first hematopoietic stem cell transplantation in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian...
Vaccine Stirs Immune Activity Against Advanced Chronic Lymphocytic Leukemia
Patients with advanced chronic lymphocytic leukemia (CLL) often receive allogeneic transplants that effectively “reboot” their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the...
No Difference in Outcome With Purged vs Nonpurged Peripheral Blood Stem Cell Transplantation in High-Risk Neuroblastoma
The contribution of purging of peripheral blood stem cells to outcome of autologous stem cell transplantation in high-risk neuroblastoma has not been defined. In a trial (COG A3973) reported in Lancet Oncology by Susan G. Kreissman, MD, of Duke University Medical Center, and colleagues, children...
Radium-223 Dichloride Prolongs Overall Survival in Men with Metastatic Prostate Cancer in Phase III ALSYMPCA Trial
In a trial (ALSYMPCA) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, United Kingdom, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and...
Cancer Survivors Have More Frequent and Severe Menopausal Hot Flashes
Women who survive cancer have more frequent, severe, and troubling hot flashes than other women with menopausal symptoms, according to a study published online in Menopause, the journal of The North American Menopause Society (NAMS). But surprisingly, the cancer survivors fare better...
Use of Androgen Deprivation Therapy for Treatment of Prostate Cancer Associated with Increased Risk of Acute Kidney Injury
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of androgen deprivation therapies, according to a study in the ...
Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...
Whole-exome Sequencing of the NCI-60 Cell Line Panel Provides a Genomic Resource for Cancer Biology and Systems Pharmacology
The NCI-60 cell lines, which represent cancers of lung, colon, brain, ovary, breast, prostate, and kidney as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As...
